Extrarenal Complications of the Nephrotic Syndrome

American Journal of Kidney Diseases

Volumn 23, Issue 4, 1994, Pages 477-497

  Harris, Raymond C ^a   Ismail, Nuhad ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

acute renal failure; calcium; edema; hypercoagulability renal vein thrombosis; hyperlipidemia; hypoalbuminemia; Nephrotic syndrome; vitamin D

Indexed keywords

CALCIUM; CORTICOSTEROID; CYTOTOXIC AGENT; DIURETIC AGENT; FUROSEMIDE; PNEUMOCOCCUS VACCINE; VITAMIN D;

ACUTE KIDNEY FAILURE; EDEMA; HUMAN; HYPERCOAGULABILITY; HYPERLIPIDEMIA; HYPOALBUMINEMIA; KIDNEY VEIN THROMBOSIS; NEPHROTIC SYNDROME; PHLEBOGRAPHY; REVIEW; SODIUM RETENTION; THROMBOEMBOLISM;

EID: 0028216202     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(12)80369-6     Document Type: Review

References (147)

1. Hepatic secretion of lipoproteins in the rat and the effect of experimental nephrosis
2. Albumin synthesis, albuminuria and hyperlipemia in nephrotic patients
3. Lowprotein diet restricts albumin synthesis in nephrotic rats
4. Metabolism of albumin and immunoglobulins in the nephrotic syndrome
5. Effect of dietary protein intake on albumin homeostasis in nephrotic patients
6. Effect of albumin concentration and colloid osmotic pressure on albumin synthesis in the perfused rat liver
7. Viscosity of culture medium as a regulator of synthesis and secretion of very low density lipoproteins by cultured hepatocytes
8. Regulation of plasma lipid levels by plasma viscosity in nephrotic rats
9. The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure, and viscosity
10. Lipid abnormalities in renal disease
11. Metabolic abnormalities in nephrotic syndrome: Pathophysiology and complications
12. Serum and urinary high-density lipoproteins in glomerular disease with proteinuria
13. Hyperlipidemia of the nephrotic syndrome
14. Lipoprotein metabolism in experimental nephrosis
15. Lipoprotein lipid and protein synthesis in experimental nephrosis and plasmapheresis. I: Studies in rat in vivo
16. Increased hepatic cholesterol production due to liver hypertrophy in rat experimental nephrosis
17. Serum lipid and lipoprotein alterations in nephrosis
18. Effects of infusions of serum albumin on serum lipids and lipoproteins in nephrosis
19. Effects on dextran, polyvinylpyrrolidone and gamma globulin on the hyperlipidemia of experimental nephrosis
20. Regulation of apolipoprotein gene expression and plasma high density lipoprotein composition in experimental nephrosis
21. Lipoprotein metabolism in experimental nephrosis
22. Apo protein CII and lipoproprotein lipase in human nephrotic syndrome
23. Pathogenesis of hyperlipidemia in the nephrotic syndrome
24. Catabolism of very low density lipoproteins in experimental nephrosis
25. The hyperlipidemia of the nephrotic syndrome
26. In vivo studies of the role of albumin in endogenous and heparin-activated lipemia-clearing in nephrotic rats
27. Characterization of glycosaminoglycans in urine from patients with nephrotic syndrome and control subjects and their effects on lipoprotein lipase
28. Lipoprotein distribution and composition in the human nephrotic syndrome
29. Experimental nephrotic syndrome in the rat induced by puromycin aminonucleoside. Plasma and urinary lipoproteins
30. Human lipoprotein lipase activation inhibitor of activity by cholesterol
31. Lipid and apolipoprotein levels in patients with nephrotic syndrome
32. Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephrotic rat
33. Catabolic defect of triglyceride is associated with abnormal very low density lipoproteins in experimental nephrosis
34. Bar-on H, Shafrir E: Experimental nephrotic syndrome: Removal and tissue distribution of chylomicrons and very-low-density lipoproteins of normal and nephrotic origin
35. Impaired renal mevalonate metabolism in nephrotic syndrome: A stimulus for increased hepatic cholesterogenesis independent of GFR and hypoalbuminemia
36. The risk of coronary artery disease among patients with the nephrotic syndrome
37. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats
38. Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome
39. Chylous ascites and the nephrotic syndrome
40. Chylothorax: A complication of the nephrotic syndrome
41. Pharmacological and dietary treatment of lipid abnormalities in nephrotic patients
42. Lovastatin in the treatment of multifactorial hyperlipidemia associated with proteinuria
43. Lipid changes in the nephrotic syndrome: New insights into pathomechanisms and treatment
44. Role for intrarenal mechanisms in the impaired salt excretion of experimental nephrotic syndrome
45. Sodium retention in nephrotic syndrome is due to an intrarenal defect: Evidence from steroid-induced remission
46. Renal function during recovery from minimal lesions nephrotic syndrome
47. Clinical course and renal function in minimal change nephrotic syndrome
48. Functional relationships in the nephrotic syndrome
49. Blood volume and sodium retention in the nephrotic syndrome: A controversial pathophysiological concept
50. Observation on edema formation in the nephrotic syndrome in adults with minimal lesions
51. Role of glomerular filtration rate in the impaired sodium and water excretion of patients with the nephrotic syndrome
52. Foot process fusion and glomerular filtration rate in minimal change nephrotic syndrome
53. Cellular basis for blunted volume expansion natriuresis in experimental nephrotic syndrome
54. Blood volume in persons with the nephrotic syndrome
55. Plasma and blood volumes in patients with nephrotic syndrome
56. Nephrotic syndrome: Vasoconstriction and hypervolemic types indicated by renin-sodium profiling
57. Plasma volume (PV) measurements in patients with nephrotic syndrome (NS): A methodological study on the labelled albumin method
58. Effect of changes in posture on circulatory homeostasis in patients with nephrotic syndrome
59. Lowered tissue-fluid oncontic pressure protects the blood volume in the nephrotic syndrome
60. A study on edema mechanisms in nephrotic syndrome
61. Lowered protein content of tissue fluid in patients with the nephrotic syndrome: Observation during disease and recovery
62. Capillary permeability to protein as a factor in the control of plasma volume. J Physio1237:39-47, 1974 63. Lassiter WE: Regulation of sodium chloride distribution within the extracellular space
63. Effect of hypoproteinemia on blood volume recovery after moderate hemorrhage in conscious splenectomized dogs
64. Restitution of blood volume after hemorrhage: Mathematical description
65. Transcapillary refilling after hemorrhage in the splenectomized dog
66. Atrial natriuretic peptide and other vasoactive hormones in nephrotic syndrome
67. v.d Meiracker AH, Roos JC, Boer P, Dorhout, Mees EJ: Effects of plasma volume expansion on renal salt handling in patients with the nephrotic syndrome
68. Atrial natriuretic peptide and the renal response to hypervolemia in nephrotic humans
69. Diuretic and hormonal responses to headout water immersion in nephrotic syndrome
70. Effects of water immersion on renal function in the nephrotic syndrome
71. Renal response to atrial peptides is reduced in experimental nephrotics
72. Preservation of blood volume during edema removal in nephrotic subjects
73. Renal failure in minimal change nephrotic syndrome
74. Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia
75. Disposition and diuretic effect of furosemide in the nephrotic syndrome
76. Furosemide binding to human albumin and plasma of nephrotic children
77. Urinary protein binding, kinetics, and dynamics of furosemide in nephrotic patients
78. Diuretics: Applied pharmacokinetics and drug resistance
79. Use of diuretics in chronic renal insufficiency and nephrotic syndrome
80. Mechanisms of furosemide resistance in analbuminemic rats and hypoalbuminemic patients
81. Albumin homeostasis in the nephrotic rat: Nutritional considerations
82. Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease
83. Modulation of albuminuria by dietary protein and converting enzyme inhibition
84. Effect of captopril on heavy proteinuria in azotemic diabetics
85. Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy
86. Kaysen GA, Schambelan M: Effect of dietary protein restriction and angiotensin converting enzyme inhibition on protein metabolism in the nephrotic syndrome
87. Treatment of nephrosis with concentrated human serum albumin. II. Effects on renal function and on excretion of water and some electrolytes
88. Saltpoor human albumin in management of nephrotic syndrome
89. Blood pressure in minimal change and other types of nephrotic syndrome
90. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin
91. Lipoid nephrosis appearing as acute oliguric renal failure
92. Reversible renal failure in the nephrotic syndrome
93. Adult minimal change glomerulopathy with acute renal failure
94. Nephrotic syndrome in children: Prediction of histopathology from clinical and laboratory characteristics at time of diagnosis
95. Hypercoagulability, renal vein thrombosis, and other thrombotic complications of the nephrotic syndrome
96. Ritze, Bommer J: Hypercoagulability in the nephrotic syndrome
97. The clinical spectrum of renal vein thrombosis: Acute and chronic
98. Thrombosis and thromboembolic complications of the nephrotic syndrome
99. Chronic renal vein thrombosis
100. Hemostasis and thromboembolism in children with nephrotic syndrome: Differences from adults
101. Thromboembolism in the nephrotic syndrome
102. Thromboembolic complication in children with nephrotic syndrome risk and incidence
103. Peripheral arterial thrombosis due to the nephrotic syndrome
104. Clinical correlation between hypercoagulability and thromboembolic phenomena
105. Nephrotic syndrome: Minimal change disease, focal glomerulosclerosis and related disorders
106. Vascular origin determines plasminogen activator expression in human endothelial cells
107. Urokinase concentration in the renal artery and vein
108. Clinical course and therapy of renal vein thrombosis
109. Renal vein thrombosis in idiopathic membranous glomerulopathy and nephrotic syndrome: Incidence and significance
110. Streptokinase salvage of renal function after renal vein thrombosis
111. Fibrinolytic therapy for bilateral renal vein thrombosis
112. Successful thrombolytic therapy in two patients with renal vein thrombosis
113. Renal vein thrombosis in the adult: A clinical and pathological study based on renal biopsies
114. Arieff Al, Massry SG: Renal vein thrombosis and nephrotic syndrome: A prospective study of 36 adult patients
115. Renal vein thrombosis in membranous glomerulopathy: Incidence and association
116. Anticoagulant, fibrinolytic, and antiplatelet therapy
117. Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin Kdependent clotting factors
118. Calcium and vitamin D homeostasis in the nephrotic syndrome: Current status
119. Urinary excretion of 25-hydroxyvitamin D in health and nephrotic syndrome
120. Vitamin-D metabolism in nephrotic syndrome
121. Decreased free 1,25-dihydroxycholecalciferol index in patients with the nephrotic syndrome
122. Vitamin D metabolites and calcium metabolism in patients with nephrotic syndrome and normal renal function
123. Calcium and vitamin D metabolism in children with nephrotic syndrome
124. Osteomalacia and hyperparathyroid bone disease in patients with nephrotic syndrome
125. Absence of metabolic bone disease in adult patients with the nephrotic syndrome and normal renal function
126. Intestinal calcium absorption in the nephrotic syndrome
127. Calcium and phosphorus metabolism in nephrotic syndrome
128. Free and total 1,25-hydroxyvitamin D levels in subjects-with renal disease
129. Vitamin D absorption, plasma concentration and urinary excretion of 25-hydroxyvitamin D in nephrotic syndrome
130. Vitamin D metabolism in nephrotic rats
131. Can urinary thyroid hormone loss cause hypothyroidism?
132. Transferrin loss into the urine with hypochromic, microcytic anemia
133. Studies on copper metabolism. XI Copper and iron metabolism in the nephrotic syndrome
134. Impaired zinc metabolic status in children affected by idiopathic nephrotic syndrome
135. Peritonitis in childhood nephrotic syndrome
136. Decline of vaccine-induced antipneumococcal antibody in children with nephrotic syndrome
137. Reduced response to HBV vaccination in boys with steroid sensitive nephrotic syndrome
138. Hepatitis B surface antigenemia and glomerulopathies in children
139. Acquired antithrombin III deficiency and thrombosis in the nephrotic syndrome
140. The role of protein C and thrombomodulin in the regulation of blood coagulation
141. Protein S deficiency occurs in the nephrotic syndrome
142. Nephrotic syndrome with renal vein thrombosis: Pathogenetic importance of a plasmin inhibitor (alpha-2-antiplasmin)
143. Molecular markers of hemostasis activation in nephrotic syndrome
144. Platelet hyperaggregability and the nephrotic syndrome
145. Platelet hyperaggregability in the nephrotic syndrome which is not dependent of arachidonic acid and serum albumin concentration